Latest / Decera Clinical Education Oncology Podcast
Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:
Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLC
Long-term safety observations for crizotinib and entrectinib
CNS activity of entrectinib and repotrectinib in patients with brain metastases
Repotrectinib activity in ROS1-TKI resistance mutations
Program faculty:
Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.